% | $
Quotes you view appear here for quick access.

ACADIA Pharmaceuticals Inc. Message Board

  • mswrichmond mswrichmond Oct 11, 2013 10:40 PM Flag

    How did we get here? Novel Agent Safe, Effective for Parkinson's Psychosis: Title of an article from

    Medscape by Caroline Cassels on April 17, 2013: American Academy of Neurology (AAN) 65th Annual Meeting. Emerging Science Session Abstract 004. Presented March 15, 2013......

    " San Diego, California — A novel, first-in-class, nondopaminergic agent that selectively blocks serotonin 5-HT2A is safe and effective for the treatment of Parkinson's disease psychosis (PDP), new research suggests.

    .......Confirming previously released topline results and reported by Medscape Medical News at that time, the phase 3 placebo-controlled trial showed that the selective nondopaminergic 5-HT2A receptor agonist pimavanserin was significantly better than placebo at reducing PDP......

    .....Since these findings were presented, the drug's manufacturer has announced that it has met with the US Food and Drug Administration. It has been agreed that the data supporting the pimavanserin as a potential treatment for PDP are sufficient to support a new drug application for this indication.

    According to a company release, this means the company will no longer conduct a phase 3 trial to confirm these results."

    Heavy insider buying between 12/13/12 to 4/3/13...ACAD jumped from $7 to $14 on 4/11/13....

    That's why we are here. But let's not get over confident. Anything can happen between now and approval day.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
34.90-0.37(-1.05%)May 26 4:00 PMEDT